The first mRNA flu shot just cleared the FDA, a year after the government tried to kill the technology
On August 5, the FDA approved mFlusiva, the first influenza vaccine ever built on mRNA, for adults 50 and older 4141. In a trial of nearly 41,000 people across 11 countries, it beat a standard flu shot by 26.6 percent overall and 27.4 percent in people 65 and up 4122.
The vaccine teaches cells to build hemagglutinin, the protein flu viruses use to break into cells, so the immune system learns to recognize it before an infection ever starts 4. The approval closes a strange loop: it comes exactly one year after Health Secretary Robert F. Kennedy Jr. canceled 22 mRNA vaccine projects worth about $500 million, calling the technology too risky, five weeks after Moderna's own trial data had already shown the opposite 63. In February, FDA official Vinay Prasad refused to even review the file; a week later, after Moderna pushed back, the agency reversed course, and Prasad left the agency in April 141.
What each field noticed (3)
Life Sciences
: the biology explains why ordinary flu shots miss some years. Hemagglutinin mutates fast, and conventional vaccines take months to manufacture, so they're sometimes chasing a strain that's already moved on. mRNA vaccines can be built and adjusted far faster 4.
Life Sciences
: the real story here was the fight to get it approved at all, tracking the reversed rejection, the ousted official, and a health secretary openly hostile to the platform he was supposed to be evaluating 141.
Social Sci.
: a biochemist's view of where this goes next. mRNA drugs are easy to reprogram since changing the therapeutic just means changing the DNA template, which is why researchers see this approval as a proof point for mRNA treatments well beyond vaccines 122.